Phase of Study

10.
Undertaking by the Investigators as per Appendix VII of Schedule Y" :-(Ethics Committee should be of same area where the site is located and details of the committee should be mentioned)
(a)
Patient Information Sheet (PIS)/ Informed consent form (ICF) as per revised Appendix V of Schedule "Y" including the following clauses. (A) Statement describing the financial compensation and medical management as under:-(a) In the event of an injury occurring to the clinical trial subjects, such subjects shall be provided free medical management as long as required. (b) In the event of a trial related injury or death, the sponsor or his representative, whosoever has obtained permission from licensing authority for conduct of clinical study shall provide financial compensation for the injury or death. (B) In serial no. 02 of an Appendix V, the following shall be included : Address of the subject: Qualification: Occupation: Student/Self-employed /service/ Housewife / Other(Please tick as appropriate) Annual income of subject: Name and address of the nominee and his/her relation to the subject (for the purpose of compensation in case of trial related death. (C) After the name of witness occurring at the end, the following shall be inserted: "Copy of the patient information sheet and duly filled ICF shall be handed over to the subject or his/her attendant"
11.(b)
Undertaking by the Sponsor/Sponsors representative/applicant to the licensing authority to provide medical management and compensation in case of clinical trial related injury or death for which subjects are entitled to compensation as required under rule 122DAB (6).
11.(c)
Declaration regarding financial status of the applicant vis-à-vis medical management and compensation to be paid to the trial participants (in case of injury or death in clinical trial).
12.
Justification for conducting the study in India:-
13.
Details of Export of Biological Samples:-
14.
Application for Export NOC for biological samples
15.
List of Investigators in India including site Address(es) (a) Trial sites detail (whether it is equipped with super specialty or multi-specialty facilities and emergency facilities with Institutional ethics committee) (b) Furnish details on the total number of trials being undertaken currently by the proposed Investigator.
16.
Name(s) of the Participating Countries
17.
Total Number of patients to be enrolled globally
18.
Total Number of patients to be enrolled in India a. Present status of proposed study in other participating countries. b. In case of premature termination/closeout of the study in other participating countries submit reasons thereof.
21.
If any Clinical trial of the Investigational Product has been Withdrawn/discontinued in any country or rejected/refused by any Regulatory Agency if so details of the same.
22.
Approvals of the proposed protocol from other participating countries (Notification to USFDA and IRB Approvals in case USA is a participating country).
23.
Ethics Committee approvals if available:-(Ethics Committee should be in same area where the site is located)
24.
Investigators Brochure:-
25.
Investigational Medicinal Products Dossier (IMPD): Affidavit declaring that the information about study drug as mentioned in Investigators Brochure is correct and based on available facts:-
(a)
27.
As per the protocol, whether the subjects will receive the Standard Care. (Give declaration)
28.
Affidavit declaring that the study has not been discontinued in any country. In case of discontinuation the reasons for such a discontinuation would be communicated:-
29.
Details of the contract entered by the sponsor with the investigator/institutions with regard to financial support, amount of fees, honorarium, payments in kind etc. to be paid to the investigator. In case no contract has yet been entered with any Investigator / Institution, plan for financial support, fees, honorarium, and payments in kind etc. to be paid to the investigator.
30.
Undertaking by the sponsor for application of marketing authorization in India after successful completion of clinical trial. Dermal toxicity (for products meant for topical (dermal) application) ii.
31.
Pre-Clinical and Clinical data
Ocular toxicity (for products meant for ocular instillation) iii.
Inhalation toxicity (conducted with the formulation proposed to be used via inhalation route) iv.
Vaginal toxicity (for products meant for topical application to vaginal mucosa) v.
Photo allergy or dermal photo toxicity (required if the drug or a metabolite is related to an agent causing photosensitivity or the nature of action suggests such a potential) vi.
Rectal tolerance test (For all preparations meant for rectal administration) e) Genotoxicity f) Allergenicity/Hypersensitivity g) Carcinogenicity (Carcinogenicity studies should be performed for all drugs that are expected to be clinically used for more than 6 months as well as for drugs used frequently in an intermittent manner in the treatment of chronic or recurrent conditions. However, completed rodent carcinogenicity studies are not needed in advance of the conduct of large scale clinical trials, unless there is a special concern for the patient population) (c) Name, address of the laboratory / laboratories with accreditation certificate /Authorization certificates for all animal toxicological reports (ii) Dose Ranging Studies (iii) Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure.
 Male fertility study  In-vitro genotoxicity tests  Relevant local toxicity studies with proposed route of clinical application (duration depending on proposed length of clinical exposure)  Allergenicity/Hypersensitivity tests (when there is a cause for concern or for parenteral drugs, including dermal application)  Photo-allergy or dermal photo-toxicity test (if the drug or a metabolite is related to an agent causing photosensitivity or the nature of action suggests such a potential)
For Phase II Clinical Trials
Provide a summary of all the non-clinical safety data (listed above) already submitted while obtaining the permissions for Phase I trial, with appropriate references.
 In case of an application for directly starting a Phase II trial -complete details of the non-clinical safety data needed for obtaining the permission for Phase I trial, as per the list provided above must be submitted.
 Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure  In-vitro and In-vivo genotoxicity tests.  Segment II reproductive/developmental toxicity study (if female patients of child bearing age are going to be involved) For Phase III Clinical Trials  Provide a summary of all the non-clinical safety data (listed above) already submitted while obtaining the permissions for Phase I and II trials, with appropriate references.
 In case of an application for directly initiating a Phase III trialcomplete details of the non-clinical safety data needed for obtaining the permissions for Phase I and II trials, as per the list provided above must be provided.  Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure  Reproductive/developmental toxicity studies  In-vitro and In-vivo genotoxicity tests  Segment I (if female patients of child bearing age are going to be involved), and  Segment III (for drugs to be given to pregnant or nursing mothers or where there are indications of possible adverse effects on foetal development) Carcinogenicity studies (when there is a cause for concern or when the drug is to be used for more than 6 months). 
31.(B)
Clinical
 Submit the Executive summary (as per the attached format) in
hard as well as soft copy.
Checklist for Protocol Amendment (GCT)
Classification for major protocol amendment:
1. Amendment with respect to age limit of subject, dose, and treatment duration. 2. Increase in number of subjects 3. Amendment in study design 4. Amendment in inclusion or exclusion criteria 5. Amendment in safety or efficacy parameters 6. Any other changes which has impact on safety of the subject TR-6 challan of required amount; bank's stamp for cheque realization (a fee of one hundred rupees for a single drug and Additional fee of fifty rupees or each additional drug).
3.
Application in Form-12 shall be duly signed, dated and stamped.The address of the site from where the product shall be imported is to be specified.
4.
Justification for quantity to be imported 5.
Copy of CT permission letter 6. GMP Status of the manufacturing site where the investigational product is manufactured. Covering letter 2.
NOTE:
Copy of CT permission letter 3.
Copy of previous protocol amendment approval letter, if any 4.
Undertaking by the Investigators as per Appendix VII of Schedule" Y":-(Ethics Committee should be of same area where the site is located.)
5.
(a) CV/ Statement of Qualification (b) Furnish details on the total number of trials being undertaken currently by the proposed Investigator. 6.
Copy of Ethics committee approval letter, if available 7.
Whether the clinical study site is a Private Clinic/Private hospital/Nursing home/ Govt. Hospital.
8.
Details of the medical facility /Hospitals: Number of beds, Whether it is equipped with super specialty or multi-specialty facilities and emergency facilities. Covering letter 2.
Reason for closure 5.
Subject enrolment status 6.
Procedure for subject follow up at the given site 7.
Copy of Ethics committee notification 8.
Copy of Ethics committee approval letter, if available 9.
Copy of summary report 10.
Safety measures after discontinuation &/or premature closure/termination of the study/study site. 11.
Ethic committee opinion for premature close-out of the study site vis-à-vis & rights of the subjects enrolled & exposed to the study drug.
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